OBIO® Highlighted Report

Bridging the Talent Gap: Report on OBIO Health to Business Bridge™ (H2BB™), 2017

Bridging the Talent Gap reports on the unique value of OBIO’s Health to Business Bridge (H2BB) business internship program. This report describes how H2BB addresses the challenge of pulling top talent into Ontario’s health science industry to address the talent gap identified by 96% of Ontario’s health science company CEOs.

Health Science Insider™ (OBIO Strategic Review: July 2016)

2016 has already been a productive year for OBIO as we push forward on our advocacy efforts, expand our Health Science networks and partnerships and continue to provide access to capital for Ontario Health Science companies in order for them to reach the next level. 

Gail Garland, CEO

OBIO

For the full strategic review, click here

PATHS TO THE FUTURE: HOW CANADA SHOULD BE ENGAGING IN A $9 TRILLION DOLLAR HEALTH ECONOMY VS. THE CANADIAN INNOVATION AGENDA

On Tuesday June 16, 2016 the first steps began towards the development of a Canadian National Inclusive Innovation Agenda. In a joint announcement the Minister of Innovation Science and Economic Development, Minister of Science, and the Minister of Small Business and Tourism unveiled 6 action areas to build an innovative Canada. 

OBIO Strategic Review: December 2015

An organization's ability to learn, and translate that learning into action rapidly, is the ultimate competitive advantage.
Jack Welch


As we come to the end of 2015, OBIO is proud of a year that has been characterized by recognition and support from our partners and sponsors, new learnings from the extensive feedback we received during our industry consultations and a very busy schedule as we delivered on programming and advocacy work.

Click here to read the article online

OBIO® Strategic Review: August 2015

They always say time changes things, but you actually have to change them yourself. 
Andy Warhol

2015 has been a year of growth and opportunity for OBIO with expanding networks and new partnerships. Since we released our five year strategic review in January 2015, there have been significant developments both within our walls and across the ecosystem.

Click here to read the article online

OBIO / OBEST Five Year Strategic Review

“The best way to predict the future is to create it”

Peter Drucker

Since its founding in 2009, the Ontario Bioscience Innovation Organization (OBIO®) has been engaged in creating the future of Ontario’s biomedical sector through industry-led strategy, policy development, advocacy and high impact programming. OBIO pursues innovative thought leadership within a culture of trust, reaching out to ever growing circles of thinkers and stakeholders.

Read the article online

Realizing the Promise of Healthcare Innovation in Ontario

The OBIO® Innovation Adoption Initiative is a product of the Ontario Bioscience Economic Strategy Team (OBEST®), an initiative launched by OBIO to address the challenges faced by Ontario’s human health technology and bioscience industry. Its goal is to recommend policy avenues that catalyze commercialization for the therapeutics, medical devices, diagnostics, and health information technology (health IT) sectors while strengthening the province’s capacity to deliver cost-effective care for patients and caregivers as intelligently and innovatively as practicable.

Click here to view the report online.

Click here to view the Innovation Adoption press release.

OBEST Strategic Implementation Plan

Why do we need a strategy? Ontario taxpayers currently spend over $44 billion annually on healthcare and $22 billion for education. The 5% projected rate of increase in (2011/12), healthcare spending is greater than the projected rate of increase for Ontario’s GDP, 2.4% (2011). The education system and academic research funding costs also continue to rise. Ontario is a leading global jurisdiction for innovation indicators, in terms of R&D spending to GDP ratio, and percentage of individuals with post-secondary training. However, Ontarians do not reap the
benefits of an innovation economy due to the underdevelopment of the biosciences industry sector. Our investments in research, novel commercial technologies, highly-qualified individuals, and smaller start-up corporations are, for the most part, lost to foreign markets. The commercial products and services developed from our innovations are then bought back by Ontarians (in the form of novel therapeutics, diagnostics, and devices) at considerable mark-up. The increased costs are not only a growing burden for tax payers, but more importantly, we as Ontarians have not benefited from the economic prosperity (jobs and wealth creation) that would result from a strong and sustainable domestic biosciences sector.

For the full report, click here

Building a Sustainable and Prosperous Bioscience Sector in Ontario: The Ontario Bioscience Industry Strategic Implementation Plan

Why do we need a strategy? Ontario taxpayers currently spend over $44 billion annually on healthcare and $22 billion for education. The 5% projected rate of increase in (2011/12), healthcare spending is greater than the projected rate of increase for Ontario’s GDP, 2.4% (2011). The education system and academic research funding costs also continue to rise. Ontario is a leading global jurisdiction for innovation indicators, in terms of R&D spending to GDP ratio, and percentage of individuals with post-secondary training. However, Ontarians do not reap the
benefits of an innovation economy due to the underdevelopment of the biosciences industry sector. Our investments in research, novel commercial technologies, highly-qualified individuals, and smaller start-up corporations are, for the most part, lost to foreign markets. The commercial products and services developed from our innovations are then bought back by Ontarians (in the form of novel therapeutics, diagnostics, and devices) at considerable mark-up. The increased costs are not only a growing burden for tax payers, but more importantly, we as Ontarians have not benefited from the economic prosperity (jobs and wealth creation) that would result from a strong and sustainable domestic biosciences sector.

 

For the full report, click here

Ontario Bioscience Industry Generated Recommendations for Sustainability and Growth in 2011 and Beyond

Ontario's life sciences companies continue to be challenged by the slow global economic recovery. Restrictions in the availability of capital continue to constrain this sector's ability to ensure Ontario's 'human capital' provides its greatest return on our societal investment.

In 2009 the Ontario Bioscience Industry Organization (OBIO™) conducted its first consultation with the Chief Executive Officers of Ontario's life sciences companies resulting in "Industry Generated Recommendations for Sustainability and Growth of Ontario's Bioscience Industry in 2010 and Beyond".

In November of 2010, OBIO conducted its second industry consultation. As with the first survey, this consultation sought to give voice to the concerns of senior life sciences executives and offer industry generated recommendations for how best to support this sector. The survey, sent to 77 C’level executives received 56 responses (73% response rate). Respondents were predominantly private companies (87%) focused on either research and development (35%) or pre-clinical research (30%). Many companies are 'pre-profit' (57%) and raising funds remains a critical focus for >90% of company leaders.

As in 2009, the 2010 survey polled executives on specific and actionable recommendations for improvements to existing funding initiatives. Chief Executives were consistent in raising concern over the level of support offered by government programs, the inefficiencies engendered by the application processes, and the challenges to their ongoing operations brought about by delays in disbursement. Accepting these opportunities for improvement, >85% of the CEO respondents consider their company's situations to be either the same or improved over the last year with the greater percentage (50%) offering that their situation has improved.

Proceeding forward, the 2010 survey offers insights as to those potential implementations considered to be of greatest value in supporting this sector. Common themes relate to 'easing' of the challenges associated with accessing existing government programs and 'easing' access to venture capital. As a measure of the commitment of industry leaders to growing their businesses within Ontario, the highest interest was accorded to "develop and implement a strategic plan for building a competitive indigenous bioscience industry in Ontario".

The 2010 OBIO CEO Consultative Survey speaks to the persistence of challenges in accessing capital and impediments to accessing both funding and markets. It gives voice to a sector which values both its productive relationship with the government of Ontario and the opportunity this survey provides to ensure government programs effectively address current needs. Importantly, this survey also serves as an initiation point for a discussion of alternative means of ensuring continued sector growth. OBIO, through OBEST™ (Ontario Bioscience Economic Strategy Team) will continue to work with industry leaders on the development of a strategic plan with the goal of delivering high value jobs, opportunities for wealth creation and improved health care for all Ontarians.

For the full report, click here